We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 38.48%
2 Communication Services 11.12%
3 Technology 9.77%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
51
Kyntra Bio
KYNB
$28.1M
$57.9M 0.39%
54,000
+14,000
+35% +$14.3M
RARX
52
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$55.8M 0.38%
+1,188,100
New +$52.5M
CVS icon
53
CVS Health
CVS
$124B
$55.7M 0.38%
750,000
-150,000
-17% -$10.5M
MNTA
54
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$54.3M 0.37%
+2,750,000
New +$44M
SRPT icon
55
CALL
Sarepta Therapeutics
SRPT
$1.79B
$51.6M 0.35%
+400,000
New +$40.4M
ARQL
56
DELISTED
Arqule Inc
ARQL
$50.3M 0.34%
+2,520,000
New +$29.2M
AXSM icon
57
Axsome Therapeutics
AXSM
$11B
$45.7M 0.31%
442,222
+42,222
+11% +$1.71M
KRTX
58
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$45.2M 0.31%
+600,000
New +$26.3M
FATE icon
59
Fate Therapeutics
FATE
$294M
$44M 0.3%
2,250,000
– –
PGNX
60
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$42M 0.28%
8,250,000
+900,000
+12% +$4.76M
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
$41.4M 0.28%
2,054,486
– –
TCDA
62
DELISTED
Tricida, Inc. Common Stock
TCDA
$37.7M 0.25%
1,000,000
+500,000
+100% +$18.6M
TVRD
63
Tvardi Therapeutics
TVRD
$23.1M
$37.1M 0.25%
63,889
+4,167
+7% +$2.92M
SAGE
64
DELISTED
Sage Therapeutics
SAGE
$36.1M 0.24%
500,000
+127,200
+34% +$15.6M
PTCT icon
65
PTC Therapeutics
PTCT
$5.86B
$34.9M 0.24%
726,986
– –
ZEAL
66
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$33.5M 0.23%
1,009,800
-200
-0% -$5.98K
MLNX
67
DELISTED
Mellanox Technologies, Ltd.
MLNX
$31.6M 0.21%
270,000
+145,000
+116% +$16.5M
TECX
68
Tectonic Therapeutic
TECX
$567M
$31.2M 0.21%
129,167
– –
TIF
69
DELISTED
Tiffany & Co.
TIF
$30.1M 0.2%
+225,000
New +$26.6M
INST
70
DELISTED
Instructure, Inc.
INST
$29.9M 0.2%
+620,000
New +$29.1M
NVTA
71
DELISTED
Invitae Corporation
NVTA
$28.2M 0.19%
1,750,000
+450,000
+35% +$7.96M
VCYT icon
72
Veracyte
VCYT
$3.71B
$27.9M 0.19%
1,000,000
– –
STML
73
DELISTED
Stemline Therapeutics, Inc.
STML
$25M 0.17%
2,350,000
+50,000
+2% +$496K
RC
74
Ready Capital
RC
$279M
$24.9M 0.17%
1,617,170
-587,962
-27% -$9.26M
QTNT
75
DELISTED
Quotient Limited Ordinary Shares
QTNT
$23.8M 0.16%
62,500
+20,000
+47% +$6.63M
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Farallon Capital Management held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Farallon Capital Management withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 40% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Farallon Capital Management opened a new position in Salesforce worth $281M.

  • Farallon Capital Management's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Farallon Capital Management added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Farallon Capital Management's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Farallon Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Farallon Capital Management's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Farallon Capital Management opened 32 new positions and closed 16 in Q4 2019.
  • Farallon Capital Management's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.